A drug that recently received accelerated approval from FDA to treat a form of non-small cell lung cancer caused by a unique genetic mutation also appears to be effective against advanced pancreatic cancer caused by the same uncommon mutation.
FDA approved Rybrevant (amivantamab-vmjw) plus Lazcluze (lazertinib) for the first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor exon 19 deletions or exon 21 L858R substitution mutations, as detected by an FDA-approved test.
